Key facts
- T&L Biological Technology’s last known valuation is $44.3M (Apr 2022).
- It has raised $14.5M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Fortune Capital, Deyuan Pharmaceutical, Fengnian Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for T&L Biological Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for T&L Biological Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About T&L Biological Technology
Developer of upstream MP-grade raw material reagents for cell and gene therapy (CGT) intended to provide reliable products and services for life sciences. The company focuses on cell and gene technologies, its products involve cell sorting magnetic bead reagents, eukaryotic/prokaryotic recombinant proteins, serum-free medium, cell culture kits, transfection reagents, and gene editing tool enzymes, offering core raw material reagents and services for biopharmaceutical and IVD fields such as cell and gene therapy drugs, antibody drug development, and cell storage.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2011
- Website
- seafrom.com/
- Ownership
- Privately Held (backing)
T&L Biological Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in T&L Biological Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on T&L Biological Technology in its N-PORT filings yet. We sweep new filings monthly.